Literature DB >> 32347747

Can melatonin reduce the severity of COVID-19 pandemic?

Alex Shneider1,2, Aleksandr Kudriavtsev3,4, Anna Vakhrusheva3.   

Abstract

The current COVID-19 pandemic is one of the most devastating events in recent history. The virus causes relatively minor damage to young, healthy populations, imposing life-threatening danger to the elderly and people with diseases of chronic inflammation. Therefore, if we could reduce the risk for vulnerable populations, it would make the COVID-19 pandemic more similar to other typical outbreaks. Children don't suffer from COVID-19 as much as their grandparents and have a much higher melatonin level. Bats are nocturnal animals possessing high levels of melatonin, which may contribute to their high anti-viral resistance. Viruses induce an explosion of inflammatory cytokines and reactive oxygen species, and melatonin is the best natural antioxidant that is lost with age. The programmed cell death coronaviruses cause, which can result in significant lung damage, is also inhibited by melatonin. Coronavirus causes inflammation in the lungs which requires inflammasome activity. Melatonin blocks these inflammasomes. General immunity is impaired by anxiety and sleep deprivation. Melatonin improves sleep habits, reduces anxiety and stimulates immunity. Fibrosis may be the most dangerous complication after COVID-19. Melatonin is known to prevent fibrosis. Mechanical ventilation may be necessary but yet imposes risks due to oxidative stress, which can be reduced by melatonin. Thus, by using the safe over-the-counter drug melatonin, we may be immediately able to prevent the development of severe disease symptoms in coronavirus patients, reduce the severity of their symptoms, and/or reduce the immuno-pathology of coronavirus infection on patients' health after the active phase of the infection is over.

Entities:  

Keywords:  Apoptosis; Bat; COVID-19; Coronavirus; Melatonin; SARS-CoV-2

Mesh:

Substances:

Year:  2020        PMID: 32347747     DOI: 10.1080/08830185.2020.1756284

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  55 in total

Review 1.  Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders.

Authors:  Adam Wichniak; Aleksander Kania; Mariusz Siemiński; Wiesław Jerzy Cubała
Journal:  Int J Mol Sci       Date:  2021-08-11       Impact factor: 5.923

2.  Obstructive Sleep Apnea with COVID-19.

Authors:  Ying Huang; DongMing Chen; Ingo Fietze; Thomas Penzel
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 3.  Sufficient Sleep, Time of Vaccination, and Vaccine Efficacy: A Systematic Review of the Current Evidence and a Proposal for COVID-19 Vaccination.

Authors:  Esmail Rayatdoost; Mohammad Rahmanian; Mohammad Sadegh Sanie; Jila Rahmanian; Sara Matin; Navid Kalani; Azra Kenarkoohi; Shahab Falahi; Amir Abdoli
Journal:  Yale J Biol Med       Date:  2022-06-30

4.  Infections, Pandemics, and Sleep Disorders.

Authors:  O V Kolokolov; E A Salina; V V Yudina; A A Shuldyakov; A E Runnova
Journal:  Neurosci Behav Physiol       Date:  2022-06-07

5.  Could dantrolene be explored as a repurposed drug to treat COVID-19 patients by restoring intracellular calcium homeostasis?

Authors:  B Jiang; S Liang; G Liang; H Wei
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-10       Impact factor: 3.507

6.  What if melatonin could help patients with severe COVID-19?

Authors:  Miguel Ángel Sánchez-González; Ignacio Mahíllo-Fernández; Felipe Villar-Álvarez; Lucía Llanos
Journal:  J Clin Sleep Med       Date:  2022-01-01       Impact factor: 4.062

7.  Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study.

Authors:  Carolina Bologna; Pasquale Madonna; Eduardo Pone
Journal:  J Clin Med       Date:  2021-12-14       Impact factor: 4.241

Review 8.  Melatonin in Early Treatment for COVID-19: A Narrative Review of Current Evidence and Possible Efficacy.

Authors:  Kristina M Cross; Dylan M Landis; Laveena Sehgal; J Drew Payne
Journal:  Endocr Pract       Date:  2021-06-10       Impact factor: 3.443

Review 9.  Pathogenesis and Management of COVID-19.

Authors:  Khalid O Alfarouk; Sari T S AlHoufie; Samrein B M Ahmed; Mona Shabana; Ahmed Ahmed; Saad S Alqahtani; Ali S Alqahtani; Ali M Alqahtani; AbdelRahman M Ramadan; Mohamed E Ahmed; Heyam S Ali; Adil Bashir; Jesus Devesa; Rosa A Cardone; Muntaser E Ibrahim; Laurent Schwartz; Stephan J Reshkin
Journal:  J Xenobiot       Date:  2021-05-21

10.  Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.

Authors:  Suvojit Hazra; Alok Ghosh Chaudhuri; Basant K Tiwary; Nilkanta Chakrabarti
Journal:  Life Sci       Date:  2020-07-15       Impact factor: 6.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.